155 related articles for article (PubMed ID: 30187322)
1. Blood Type as a Predictor of High-Grade Dysplasia and Associated Malignancy in Patients with Intraductal Papillary Mucinous Neoplasms.
Poruk KE; Griffin J; Makary MA; He J; Cameron JL; Weiss MJ; Wood LD; Goggins M; Wolfgang CL
J Gastrointest Surg; 2019 Mar; 23(3):477-483. PubMed ID: 30187322
[TBL] [Abstract][Full Text] [Related]
2. MUC2 expression and prevalence of high-grade dysplasia and invasive carcinoma in mixed-type intraductal papillary mucinous neoplasm of the pancreas.
Masuda A; Arisaka Y; Hara S; Matsumoto I; Takenaka M; Sakai A; Shiomi H; Matsuki N; Sugimoto M; Fujita T; Hayakumo T; Ku Y; Ogino S; Azuma T; Kutsumi H
Pancreatology; 2013; 13(6):583-8. PubMed ID: 24280573
[TBL] [Abstract][Full Text] [Related]
3. Oncocytic-type intraductal papillary mucinous neoplasms: a unique malignant pancreatic tumor with good long-term prognosis.
Marchegiani G; Mino-Kenudson M; Ferrone CR; Warshaw AL; Lillemoe KD; Fernández-del Castillo C
J Am Coll Surg; 2015 May; 220(5):839-44. PubMed ID: 25840549
[TBL] [Abstract][Full Text] [Related]
4. Development and Validation of a Multi-institutional Preoperative Nomogram for Predicting Grade of Dysplasia in Intraductal Papillary Mucinous Neoplasms (IPMNs) of the Pancreas: A Report from The Pancreatic Surgery Consortium.
Attiyeh MA; Fernández-Del Castillo C; Al Efishat M; Eaton AA; Gönen M; Batts R; Pergolini I; Rezaee N; Lillemoe KD; Ferrone CR; Mino-Kenudson M; Weiss MJ; Cameron JL; Hruban RH; D'Angelica MI; DeMatteo RP; Kingham TP; Jarnagin WR; Wolfgang CL; Allen PJ
Ann Surg; 2018 Jan; 267(1):157-163. PubMed ID: 28079542
[TBL] [Abstract][Full Text] [Related]
5. Current recommendations for surveillance and surgery of intraductal papillary mucinous neoplasms may overlook some patients with cancer.
Nguyen AH; Toste PA; Farrell JJ; Clerkin BM; Williams J; Muthusamy VR; Watson RR; Tomlinson JS; Hines OJ; Reber HA; Donahue TR
J Gastrointest Surg; 2015 Feb; 19(2):258-65. PubMed ID: 25373706
[TBL] [Abstract][Full Text] [Related]
6. Intraductal papillary mucinous neoplasms of the pancreas: an updated experience.
Sohn TA; Yeo CJ; Cameron JL; Hruban RH; Fukushima N; Campbell KA; Lillemoe KD
Ann Surg; 2004 Jun; 239(6):788-97; discussion 797-9. PubMed ID: 15166958
[TBL] [Abstract][Full Text] [Related]
7. Intraductal papillary mucinous neoplasm (IPMN) with high-grade dysplasia is a risk factor for the subsequent development of pancreatic ductal adenocarcinoma.
Rezaee N; Barbon C; Zaki A; He J; Salman B; Hruban RH; Cameron JL; Herman JM; Ahuja N; Lennon AM; Weiss MJ; Wood LD; Wolfgang CL
HPB (Oxford); 2016 Mar; 18(3):236-46. PubMed ID: 27017163
[TBL] [Abstract][Full Text] [Related]
8. Management and outcomes of intraductal papillary mucinous neoplasms.
Hipp J; Mohamed S; Pott J; Sick O; Makowiec F; Hopt UT; Fichtner-Feigl S; Wittel UA
BJS Open; 2019 Aug; 3(4):490-499. PubMed ID: 31388641
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical FAP Expression Reflects
Spektor AM; Gutjahr E; Lang M; Glatting FM; Hackert T; Pausch T; Tjaden C; Schreckenberger M; Haberkorn U; Röhrich M
J Nucl Med; 2024 Jan; 65(1):52-58. PubMed ID: 38167622
[TBL] [Abstract][Full Text] [Related]
10. Long-term prospective cohort study of patients undergoing pancreatectomy for intraductal papillary mucinous neoplasm of the pancreas: implications for postoperative surveillance.
Kang MJ; Jang JY; Lee KB; Chang YR; Kwon W; Kim SW
Ann Surg; 2014 Aug; 260(2):356-63. PubMed ID: 24378847
[TBL] [Abstract][Full Text] [Related]
11. Pancreatic main-duct involvement in branch-duct IPMNs: an underestimated risk.
Fritz S; Klauss M; Bergmann F; Strobel O; Schneider L; Werner J; Hackert T; Büchler MW
Ann Surg; 2014 Nov; 260(5):848-55; discussion 855-6. PubMed ID: 25379856
[TBL] [Abstract][Full Text] [Related]
12. Pancreatic Resection for Side-Branch Intraductal Papillary Mucinous Neoplasm (SB-IPMN): a Contemporary Single-Institution Experience.
Dortch JD; Stauffer JA; Asbun HJ
J Gastrointest Surg; 2015 Sep; 19(9):1603-9. PubMed ID: 26055134
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic study of the MIB-1 labeling index (Ki67) and postoperative prognosis for intraductal papillary mucinous neoplasms and ordinary ductal adenocarcinoma.
Takeshita A; Kimura W; Hirai I; Takasu N; Moriya T; Tezuka K; Watanabe T
Pancreas; 2012 Jan; 41(1):114-20. PubMed ID: 22143341
[TBL] [Abstract][Full Text] [Related]
14. Pancreatic juice cytology as sensitive test for detecting pancreatic malignancy in intraductal papillary mucinous neoplasm of the pancreas without mural nodule.
Kawada N; Uehara H; Nagata S; Tomita Y; Nakamura H
Pancreatology; 2016; 16(5):853-8. PubMed ID: 27459913
[TBL] [Abstract][Full Text] [Related]
15. ABO blood group distribution and risk of malignancy in patients undergoing resection for intraductal papillary mucinous neoplasm (IPMN).
Zelga P; Hernández-Barco YG; Qadan M; Ferrone CR; Baba T; Bolm L; Jah A; Warshaw AL; Lillemoe KD; Balakrishnan A; Fernández-Del Castillo C
Pancreatology; 2022 Mar; 22(2):264-269. PubMed ID: 35000863
[TBL] [Abstract][Full Text] [Related]
16. High-Grade Dysplasia in Resected Main-Duct Intraductal Papillary Mucinous Neoplasm (MD-IPMN) is Associated with an Increased Risk of Subsequent Pancreatic Cancer.
Majumder S; Philip NA; Singh Nagpal SJ; Takahashi N; Mara KC; Kendrick ML; Smyrk TC; Zhang L; Levy MJ; Gleeson FC; Petersen BT; Pearson RK; Topazian MD; Vege SS; Chari ST
Am J Gastroenterol; 2019 Mar; 114(3):524-529. PubMed ID: 30413822
[TBL] [Abstract][Full Text] [Related]
17. Can contrast-enhanced harmonic endoscopic ultrasonography accurately diagnose main pancreatic duct involvement in intraductal papillary mucinous neoplasms?
Ohno E; Kawashima H; Ishikawa T; Iida T; Suzuki H; Uetsuki K; Yashika J; Yamada K; Yoshikawa M; Gibo N; Aoki T; Kataoka K; Mori H; Hirooka Y; Fujishiro M
Pancreatology; 2020 Jul; 20(5):887-894. PubMed ID: 32651080
[TBL] [Abstract][Full Text] [Related]
18. Long-term Risk of Pancreatic Malignancy in Patients With Branch Duct Intraductal Papillary Mucinous Neoplasm in a Referral Center.
Pergolini I; Sahora K; Ferrone CR; Morales-Oyarvide V; Wolpin BM; Mucci LA; Brugge WR; Mino-Kenudson M; Patino M; Sahani DV; Warshaw AL; Lillemoe KD; Fernández-Del Castillo C
Gastroenterology; 2017 Nov; 153(5):1284-1294.e1. PubMed ID: 28739282
[TBL] [Abstract][Full Text] [Related]
19. What is the Incidence of Malignancy in Resected Intraductal Papillary Mucinous Neoplasms? An Analysis of Over 100 US Institutions in a Single Year.
Khoury RE; Kabir C; Maker VK; Banulescu M; Wasserman M; Maker AV
Ann Surg Oncol; 2018 Jun; 25(6):1746-1751. PubMed ID: 29560572
[TBL] [Abstract][Full Text] [Related]
20. Endoscopic ultrasonographic findings predict the risk of carcinoma in branch duct intraductal papillary mucinous neoplasms of the pancreas.
Kobayashi N; Sugimori K; Shimamura T; Hosono K; Watanabe S; Kato S; Ueda M; Endo I; Inayama Y; Maeda S; Nakajima A; Kubota K
Pancreatology; 2012; 12(2):141-5. PubMed ID: 22487524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
